Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study
- PMID: 32176629
- DOI: 10.3233/CBM-191018
Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study
Abstract
Background: Minimal invasive blood-based molecular markers are evaluated as promising biomarkers in malignant diseases these days.
Objective: In this pilot study, we investigated the potential of cell-free DNA (cfDNA) concentration and cell-free DNA Integrity (cfDI) as blood-based diagnostic markers for ovarian cancer patients in a retrospective study cohort.
Methods: cfDNA concentration and cfDI were determined in the plasma of 37 ovarian cancer patients and 28 healthy controls, by measuring ALU and LINE1 repetitive DNA elements using quantitative real-time PCR.
Results: A high correlation was observed between the results of ALU and LINE1. The correlated co-efficiency between the values of cfDNA concentration and cfDI was 0.86 and 0.71. As for the results between cases and controls, no or just borderline significant difference was observed in cfDI after age adjustment (P= 0.40 for ALU and P= 0.05 for LINE1) while cfDNA concentration showed a significant difference between ovarian cancer patients and healthy controls groups (P= 0.03 for ALU and P= 3.00 E-03 for LINE1). cfDNA concentration of ALU and LINE1 had an AUC of 0.81 (0.70-0.91). ALU and LINE1 cfDI reached an AUC of 0.60 (95% CI: 0.46-0.73). The combination of these markers reached the best diagnostic power with an AUC of 0.84.
Conclusions: cfDNA variables might be potentially diagnostic biomarkers in ovarian cancer, in combination with additional molecular markers. However, further studies are needed to confirm the diagnostic ability of cfDNA variables (cfDNA concentration and cfDI).
Keywords: Ovarian cancer; cell free DNA concentration; cell free DNA integrity; diagnostic marker.
Similar articles
-
Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.Breast Cancer Res Treat. 2018 May;169(1):69-82. doi: 10.1007/s10549-018-4666-5. Epub 2018 Jan 16. Breast Cancer Res Treat. 2018. PMID: 29340881
-
Alter circulating cell-free DNA variables in plasma of ovarian cancer patients.J Obstet Gynaecol Res. 2019 Nov;45(11):2237-2242. doi: 10.1111/jog.14102. Epub 2019 Sep 9. J Obstet Gynaecol Res. 2019. PMID: 31502389
-
Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis.Breast Cancer Res Treat. 2014 Jul;146(1):163-74. doi: 10.1007/s10549-014-2946-2. Epub 2014 May 17. Breast Cancer Res Treat. 2014. PMID: 24838941
-
Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.Gene. 2019 Sep 25;714:143993. doi: 10.1016/j.gene.2019.143993. Epub 2019 Jul 19. Gene. 2019. PMID: 31330238 Review.
-
Cell-Free Circulating DNA Integrity Based on Peripheral Blood as a Biomarker for Diagnosis of Cancer: A Systematic Review.Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1595-1602. doi: 10.1158/1055-9965.EPI-17-0502. Epub 2017 Aug 22. Cancer Epidemiol Biomarkers Prev. 2017. PMID: 28830871 Review.
Cited by
-
Can Circulating Cell-Free DNA or Circulating Tumor DNA Be a Promising Marker in Ovarian Cancer?J Oncol. 2021 Apr 12;2021:6627241. doi: 10.1155/2021/6627241. eCollection 2021. J Oncol. 2021. PMID: 33936202 Free PMC article. Review.
-
Plasma Cell-Free DNA as a Novel Biomarker for the Diagnosis and Monitoring of Atherosclerosis.Cells. 2022 Oct 16;11(20):3248. doi: 10.3390/cells11203248. Cells. 2022. PMID: 36291116 Free PMC article.
-
ALU repeat as potential molecular marker in the detection and prognosis of different cancer types: A systematic review.Mol Clin Oncol. 2022 Apr;16(4):86. doi: 10.3892/mco.2022.2519. Epub 2022 Feb 21. Mol Clin Oncol. 2022. PMID: 35251637 Free PMC article.
-
Mutation profiles in circulating cell-free DNA predict acquired resistance to olaparib in high-grade serous ovarian carcinoma.Cancer Sci. 2022 Aug;113(8):2849-2861. doi: 10.1111/cas.15456. Epub 2022 Jun 26. Cancer Sci. 2022. PMID: 35661486 Free PMC article.
-
The Role of Circulating Tumor DNA in Ovarian Cancer.Cancers (Basel). 2024 Sep 10;16(18):3117. doi: 10.3390/cancers16183117. Cancers (Basel). 2024. PMID: 39335089 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials